• Patient Perception of Treatment Benefit at Week 12:
  
• Treatment benefit, treatment satisfaction, and willingness to continue treatment questions at week 12
  

• Micturition Diary- •Change in number of urge incontinence episodes per 24 hours at week 1, week 6 and 12
  
• relative to baseline
  
• Change in number of urge episodes per 24 hours at week 1, week 6 and 12 relative to
  
• baseline
  
• Change in number of micturitions per 24 hours at week 1, week 6 and 12 relative to
  
• Change in number of daytime micturitions per 24 hours at week 1, week 6 and 12 relative to baseline
  
• Change in number of nighttime micturitions per 24 hours at week 1, week 6 and 12 relative to baseline
  
• Change in the average severity of the Urinary Sensation Scale at week 1, week 6, and week 12 relative to baseline
  
• Change in number of OAB micturition episodes per 24 hours (OAB micturition is defined as
  
• micturition episodes associated with Urinary Sensation Scale score  3) at week 1, week 6 and week 12 relative to baseline
  
• Change in number of daytime OAB micturition episodes per 24 hours
  
• (OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score  3) at week 1, week 6 and week 12 relative to baseline
  
• Change in number of nighttime OAB micturition episodes per 24 hours
  
• Change in number of severe OAB micturition episodes per 24 hours
  
• (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score  4) at week 1, week 6 and week 12 relative to baseline
  
• Change in number of daytime severe OAB micturition episodes per 24 hours
  
• Change in number of nighttime severe OAB micturition episodes per 24 hours
  
• International Prostate Symptom Score (I-PSS):
  
• Change in I-PSS total score at weeks 1, 6 and 12 relative to baseline
  
• Change in I-PSS individual item scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) at weeks 1, 6 and 12 relative to baseline
  
• Change in I-PSS irritative domain (Sum of Q2, Q4, and Q7) at weeks 1, 6 and 12 relative to baseline
  
• Change in I-PSS obstructive domain (Sum of Q1, Q3, Q5, and Q6) at weeks 1, 6 and 12 relative to baseline
  
• Change in I-PSS index score (Sum Q1 to Q7) at weeks 1, 6 and 12 relative to baseline
  
• Change in I-PSS QoL score (Q8) at weeks 1, 6 and 12 relative to baseline
  
• Patient perception of urgency:
  
• Change in the Perception of Urgency Scale (3 point scale) at week 1, week 6 and week 12 relative to baseline
  
• Change in Patient’s Perception of Bladder Condition at week 1, week 6 and week 12 relative to baseline
  
• Patient Perception of Treatment benefit at week 1 and week 6
  
• Treatment benefit and treatment satisfaction questions will be completed at week 1
  
• and week 6
  
• Change in International Continence Society Male (ICSmaleLF) Questionnaire (long form modified) individual item scores at Week 1, Week 6 and Week 12 relative to baseline
  
• Change in the total score of Overactive Bladder Questionnaire (OABq) and change in total scores for each domain of OABq at week 6 and week 12 relative to baseline
  
• Change in the total score of International Index of Erectile Function (IIEF) and change in total scores for each domain of IIEF Questionnaire at week 6 and week 12 relative to baseline
  

Inclusion Criteria:

• Male 40 years of age
• Clinical signs and symptoms of frequency and urgency, with or without UUI, with or without BOO, for at least three months
• Mean urinary frequency of 8 micturitions/24h verified by the Screening micturition diary

Exclusion Criteria:

• Post-void residual urine volume (PVR) of > 200 ml as measured by an ultrasound
• Maximum urinary flow rate (Qmax) of < 5 ml/second as measured by a flowmeter; a voided volume of 75 ml is required in order to accurately record the Qmax
• Prescribed and administered an antimuscarinic or antispasmodic within 1 month
• Prescribed and administered an a-1-adrenergic antagonist within 2 weeks